Qi Jingbo, Hu Zhiqiu, Liu Shaoqun, Li Fan, Wang Sheng, Wang Wuqing, Sheng Xia, Feng Li
Endoscopy Center, Minhang Hospital, Fudan University and Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
Department of Surgical, Minhang Hospital, Fudan University, Shanghai, China.
Front Oncol. 2021 Jan 18;10:618902. doi: 10.3389/fonc.2020.618902. eCollection 2020.
Colorectal cancer (CRC) is the third most common cancer worldwide. Here, we identified tumor-associated macrophages (TAMs) as regulators of genes in CRC. In total, the expressions of 457 genes were dysregulated after TAM coculture; specifically, 344 genes were up-regulated, and 113 genes were down-regulated. Bioinformatic analysis implied that these TAM-related genes were associated with regulation of the processes of macromolecule metabolism, apoptosis, cell death, programmed cell death, and the response to stress. To further uncover the interplay among these proteins, we constructed a PPI network; 15 key regulators were identified in CRC, including VEGFA, FN1, JUN, CDH1, MAPK8, and FOS. Among the identified genes, we focused on PSMA2 and conducted loss-of-function experiments to validate the functions of PSMA2 in CRC. To further determine the mechanism by which PSMA2 affected CRC, we conducted multiple assays in CRC cell lines and tissues. PSMA2 enhanced the proliferation, migration and invasion of CRC cells. Moreover, our data indicated that PSMA2 expression was dramatically increased in stage 1, stage 2, stage 3, and stage 4 CRC samples. Our data indicated that PSMA2 was one target of miR-132. A miR-132 mimic greatly hindered CRC cell proliferation. In addition, the luciferase assay results revealed that miR-132 directly regulated PSMA2. Moreover, our data indicated that miR-132 expression was greatly decreased in CRC samples, which was associated with longer survival times of CRC patients, implying that miR-132 was a probable biomarker for CRC. Collectively, these data indicate that PSMA2 is a promising target for the therapy of CRC.
结直肠癌(CRC)是全球第三大常见癌症。在此,我们将肿瘤相关巨噬细胞(TAM)鉴定为CRC中基因的调节因子。共培养TAM后,共有457个基因的表达失调;具体而言,344个基因上调,113个基因下调。生物信息学分析表明,这些与TAM相关的基因与大分子代谢、凋亡、细胞死亡、程序性细胞死亡以及应激反应过程的调节有关。为了进一步揭示这些蛋白质之间的相互作用,我们构建了一个蛋白质-蛋白质相互作用(PPI)网络;在CRC中鉴定出15个关键调节因子,包括血管内皮生长因子A(VEGFA)、纤连蛋白1(FN1)、原癌基因蛋白c-Jun(JUN)、钙黏蛋白1(CDH1)、丝裂原活化蛋白激酶8(MAPK8)和原癌基因蛋白c-Fos(FOS)。在鉴定出的基因中,我们聚焦于前列腺特异性膜抗原2(PSMA2),并进行了功能丧失实验以验证PSMA2在CRC中的功能。为了进一步确定PSMA2影响CRC的机制,我们在CRC细胞系和组织中进行了多项实验。PSMA2增强了CRC细胞的增殖、迁移和侵袭能力。此外,我们的数据表明,PSMA2在I期、II期、III期和IV期CRC样本中的表达显著增加。我们的数据表明,PSMA2是微小RNA-132(miR-132)的一个靶标。miR-132模拟物极大地抑制了CRC细胞的增殖。此外,荧光素酶检测结果显示,miR-132直接调控PSMA2。而且,我们的数据表明,miR-132在CRC样本中的表达大幅降低,这与CRC患者较长的生存时间相关,这意味着miR-132可能是CRC的一个生物标志物。总体而言,这些数据表明PSMA2是CRC治疗的一个有前景的靶点。